What drives us
Our world-class research infrastructure offers accessible and streamlined access to over 460,000 cancer biospecimens and a rich repository of associated clinical data. We also offer bespoke prospective collections and specimen services for clinical trials.
This invaluable biobanking infrastructure is made possible through the joint effort of the VCB consortium, as well as donations from almost 40,000 Victorians. Their generosity has supported over 300 academic and commercial research projects, resulting in over 300 highly impactful scientific publications and a number of successful commercialisations.
Learn more
Our team will work with you for all your research project needs.
Biobanking and biospecimen related services for supporting clinical trials and other studies.
The VCB has been instrumental in empowering researchers and facilitating ground breaking scientific discoveries.
Our biospecimen archive
Our extensive collection of biospecimens has been generously donated by Victorians willing to contribute to cancer research. Explore our interactive data to gain a real-time snapshot into our inventory and understand the broad range of cancer and specimen types available within our archive. Click the 3 dots for more graph options.
The VCB is a critical infrastructure that provides vital resources for researchers to improve cancer outcomes, and we’re proud to support their pioneering work to change and save lives – it’s innovations like these that demonstrate why the Victorian Government’s investment in medical research is so critically important.
Honorary Ben Carroll, Minister for Medical Research
Victorian Government
The support provided by the VCB, which included recruitment and provision of high-quality blood samples from donor participants, was instrumental for the foundational biomarker discovery and development work that we undertook at CSIRO, which has been critical for commercial success.
Dr Kim Fung, Principal Research Scientist
CSIRO
The support provided by the VCB, its staff, and its network of hospitals, and in particular the generosity of its sample donors, have all been critical in enabling the great progress that our company has made in developing a new, simple, blood-based diagnostic test for the early detection of colorectal cancer and our other target cancers.”
Dr Trevor Lockett, Technical Director
Rhythm Biosciences
The Victorian Cancer Biobank is marking 20 years at the forefront of cancer research – a milestone that underscores its role as one of Australia’s most powerful engines for life-saving discovery.
The Victorian Cancer Biobank (VCB) has submitted a comprehensive response to the Australian Law Reform Commission’s review of Human Tissue Laws (HTA), advocating for reforms that better support ethical, equitable, and impactful research.
We are pleased to present our key achievements and impact for the 2023–24 financial year, highlighting the progress, contributions, and outcomes delivered through our biobanking efforts in support of cancer research.